Administration of DDAVP did not improve the pharmacokinetics of FVIII concentrate in a clinically significant manner
Background: The half-life and mean residence time (MRT) of infused recombinant factor VIII (FVIII) concentrate are associated with pre-infusion levels of von Willebrand factor (VWF) in severely affected hemophilia A patients. It is currently unknown if individual FVIII concentrate half-life and MRT can be extended by increasing endogenous VWF levels.
Aim: Our aim was to evaluate the effect of a 1-deamino-8-D-arginine vasopressin (DDAVP)-induced rise in VWF concentration on the pharmacokinetics of infused FVIII in hemophilia A patients.
Methods: Four adult hemophilia A patients participated in this cross-over, placebo controlled study. Each patient received either intravenous DDAVP or placebo, one hour prior to administration of 50 IU/kg plasma-derived immune-affinity purified FVIII concentrate.
Results: The combined administration of DDAVP and FVIII concentrate was well tolerated. The levels of VWF Antigen (Ag) doubled after DDAVP, whereas they remained stable after placebo infusion. This rise in VWF Ag resulted in a slight modification of the pharmacokinetic parameters of FVIII concentrate. The MRT of FVIII concentrate increased in all patients (mean from 17.6 h to 19.9 h, p < 0.001, 95% CI for MRT change: +4.7 to -0.3 h). However, in vivo recoveries tended to decrease following DDAVP administration.
Conclusions: Collectively, these data show that administration of DDAVP did not improve the pharmacokinetics of FVIII concentrate in a clinically significant manner.
Relevance for patients: Our results indicate that no clinical benefit is to be expected from the modification in FVIII pharmacokinetics resulting from DDAVP-administration prior to infusion of FVIII concentrate in hemophilia A patients.
[1] Fijnvandraat K, Cnossen MH. Diagnosis and management of haemophilia. BMJ, 2012: 2707:1-5.
[2] Björkman S, Oh M, Spotts G, Schroth P, Fritsch S, Ewenstein BM, Casey K, Fischer K, Blanchette VS, Collins PW. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012; 119: 612-618.
[3] Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand’s disease. J Clin Invest 1977; 60: 390-404.
[4] Pipe SW, Montgomery RR, Pratt, KP, Lenting PJ, Lillicrap D. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood 2016; 128: 2007-2016.
[5] Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003; 1: 682-689.
[6] Stockschlaeder M, Schneppenheim R, Budde U. Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis 2014; 25: 206-216.
[7] Rotondo F, Butz H, Syro LV, Yousef GM, Di IA, Restrepo LM, Quintanar-Stephano A, Berczi I, Kovacs K. Arginine vasopressin (AVP): a review of its historical perspectives, current research and multifunctional role in the hypothalamo hypophysial system. Pituitary 2016; 19: 345-355.
[8] Rondaij MG, Bierings R, Kragt A, Van Mourik JA, Voorberg J. Dynamics and plasticity of Weibel-Palade bodies in endothelial cells. Arterioscler Thromb Vasc Biol, 2006: 26: 1002-1007.
[9] Kaufmann JE, Oksche A, Wollheim CB, Günther G, RosenthalW, Vischer UM. Vasopressin-induced von Willebrand factorsecretion from endothelial cells involves V2 receptors andcAMP Vasopressin-induced von Willebrand factor secretionfrom endothelial cells involves V2 receptors and cAMP. J ClinInvest, 2000; 106:107-116
[10]Morfini M, Mannucci PM, Tenconi PM, Longo G, Mazzucconi MG, Rodeghiero F, Ciavarella N, De Rosa VAA. Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease. Thromb Haemost 1993; 70:270-272.
[11] Cattaneo M, Moia M, Delle VP, Castellana P, Mannucci PM. DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor. Blood 1989; 74: 1972-1975.
[12] Hellstern P, Kiehl R, Miyashita C, Schwerdt H, von BG, Khler M, Büttner M, Wenzel E. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A-comparison of one-stage assay, two-stage assay and a chromogenic substrate assay. Thromb Haemost 1986; 56:353-359.
[13] Fijnvandraat K, Peters M, TenCate JW. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol 1995; 91:474-476.
[14] Fischer K, Pendu R, Schooten VCJ, Dijk VK, Denis CV, van den Berg HM, Lenting PJ. Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients. PLoS One 2009; 4: e6745.
[15] Vlot AJ, Mauser-Bunschoten EP ZA. The Half-life of Infused Factor VIII Is Shorter in Hemophiliac Patients with Blood Group 0 than in those with Blood Group A. Thromb Haemost Haemost. 2000;83:65–9.
[16] Messori A, Longo G, Morfini M, Cinotti S, Filimberti E, Giustarini G, Rossi Ferrini P. Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs. Eur J Clin Pharmacol 1988; 35:663-668.
[17] Van DK, Bom VDJG, Lenting PJ, Groot PG, Mauser bunschoten EP, Roosendaal G, Grobbee DE, van den Berg HM. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica 2005;90: 494-498.
[18] Barnes C, Lillicrap D, Stain AM, Hensmen C, Carcao M, Sciences H, et al. Pharmacokinetics of recombinant factor VIII (Kogenate-FS Ò) in children and causes of inter-patient pharmacokinetic variability. Haemophilia. 2006; 12: 40-49.
[19] Colucci G, Stutz M, Rochat S, Conte T, Pavicic M, Reusser M, Giabbani E, Huynh A, Thürlemann C, Keller P, Alberio L. The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects. Blood 2014; 123: 1905-1916.
[20] Deitcher SR, Tuller J, Johnson JA. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients. Haemophilia, 1999; 5: 88-95.
[21] Morfini M, Lee M, Messori A. The design and analysis of half life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost, 1991; 66:384-386.
[22] Vossebeld PJM, Tissing MH, Van Den Berg HM. Leebeek FW, De Goede-Bolder A, NovAkovA IR, Gerrits WB, Peters M, Koopman MM, Faber A, Hiemstra H, Grob P, Strengers PF. In vivo recovery and safety human factor VIII product AAFACT in patients with haemophilia A. Haemophilia 2003; 9: 157-163.
[23]Lenting PJ, Donath MJ, Van Mourik JA, Mertens K. Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem 1994;269:7150-7155.
[24]Borchiellini A, Fijnvandraat K, Ten Cate JW, Pajkrt D, van Deventer SJ, Pasterkamp G, Meijer-Huizinga F, Zwart-Huinink L, Voorberg J, van Mourik JA. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8 D-arginine vasopressin in humans. Blood 1996; 88: 2951-2958.
[25] Björkman S, Carlsson M. The pharmacokinetics of factor VIII and factor IX: methodology, pitfalls and applications. Haemophilia 1997; 3: 1-8.
[26]Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6:217-246.
[27] Noe DA. A Mathematical Model of Coagulation Factor VIII Kinetics. Pathophysiol Haemost Thromb 1996; 26:289-303.
[28]Over J, Sixma JJ, Doucet De Bruine HM. Survival of 125Iodine-labeled factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human factor VIII. J Clin Invest 1978; 62:223-234.
[29]Rugger ZM, Mannucci PM, Lombardi R, Federici AB, Zimmerman TS. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand’s disease subtypes. Blood 1982; 59: 1272-1278.
[30]Fischer BE, Kramer G, Mitterer A, Grillberger L, Reiter, M, Mundt W, Dorner F, Eibl J. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII. Thromb Res 1996; 84:55-66.
[31]Vlot AJ, Koppelman SJ, Meijers JC, Dama C, van den Berg HM, Bouma BN, Sixma JJ, Willems GM. Kinetics of factor VIII- von Willebrand factor association. Blood 1996; 87: 1809-1816.
[32]Stoddart JH, Andersen J, Lynch DC. Clearance of normal and type 2A von Willebrand factor in the rat. Blood 1996; 88: 1692-1699.
[33]Leyte A, Verbeet MP, Brodniewicz-Proba T, van Mourik JA, Mertens K. The interaction between human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high affinity binding site on factor VIII. Biochem J 1989; 257: 679-683.
[34]Lollar P, Parker CG. Stoichiometry of the porcine factor VIII- von Willebrand factor association. J Biol Chem 1987; 262:17572-17576.
[35]Leyte A, van Schijndel HB, Niehrs C, Huttner WB, Verbeet MP, Mertens K, van Mourik JA. Sulfation of Tyr1680 of human blood coagulation Factor VIII is essential for the interaction of Factor VIII with von Willebrand factor. J Biol Chem 1991; 266:740-746.
[36]Eckhardt CL, van Velzen AS, Peters M, Astermark J, Brons PP, Castaman G, Cnossen MH, Dors N, Escuriola-Ettingshausen C, Hamulyak K, Hart DP, Hay CR, Haya S, van Heerde WL, Hermans C, Holmström M, Jimenez-Yuste V, Keenan RD, Klamroth R, Laros-van Gorkom BA, Leebeek FW, Liesner R, Mäkipernaa A, Male C, Mauser-Bunschoten E, Mazzucconi MG, McRae S, Meijer K, Mitchell M, Morfini M, Nijziel M, Oldenburg J, Peerlinck K, Petrini P, Platokouki H, Reitter Pfoertner SE, Santagostino E, Schinco P, Smiers FJ, Siegmund B, Tagliaferri A, Yee TT, Kamphuisen PW, van der Bom JG, Fijnvandraat K; INSIGHT Study Group. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood 2013; 122:1954-1962.